Jentadueto

(Linagliptin and metformin hydrochloride)

Jentadueto

Drug updated on 11/27/2023

Dosage FormTablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information.2023Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
316Subjects
F: 54%
M: 46%
2016Postgraduate Medicine

Sex Distribution:

F:54%
M:46%
316Subjects

Year:

2016

Source:Postgraduate Medicine

Clinical Practice Guidelines